Transitory Beneficial Effects of Professional Continuous Glucose Monitoring on the Metabolic Control of Patients with Type 1 Diabetes

Patrascioiu, Ioana; Quirós, Carmen; Rios, Paola; Ruíz, Montserrat; Mayordomo, Rosa; Conget, Ignacio; Giménez, Marga

doi:10.1089/dia.2013.0266

Cited by 3 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no reported improvement in A1C, 7 months after the intervention in a retrospective study that included 102 patients with T1 and T2DM. 77 Others have reported an improvement on A1C in hyperglycemic patients with T1DM 78 and both T1 and T2DM, 78,79 and in patients with T2DM, having mainly hypoglycemia 78 ; in this same study, there was no change in A1C in patients classified as having fluctuating glucose levels with either form of DM. 79 Durability of glucose control after PCGM revealed that the improvement at 3-5 months after PCGM was lost after 1 year.…”

Section: Professional Retrospective Cgmsupporting

confidence: 48%

“…79 Durability of glucose control after PCGM revealed that the improvement at 3-5 months after PCGM was lost after 1 year. 78 An improvement in selfreported hypoglycemia has been observed. 78,79 There are no randomized control trials or clinical guidelines on the indications for this technology.…”

Section: Professional Retrospective Cgmmentioning

confidence: 89%

“…78 An improvement in selfreported hypoglycemia has been observed. 78,79 There are no randomized control trials or clinical guidelines on the indications for this technology. Previous retrospective studies have included hypo-and hyperglycemia, 79 in addition to GV 78 as reasons for providers to prescribe this technology to patients.…”

Section: Professional Retrospective Cgmmentioning

confidence: 89%

“…78,79 There are no randomized control trials or clinical guidelines on the indications for this technology. Previous retrospective studies have included hypo-and hyperglycemia, 79 in addition to GV 78 as reasons for providers to prescribe this technology to patients. Our group identified GV and hyperglycemia as the most common indications for ordering a PCGM in an academic setting, and described improvements in A1C without a significant change in frequency of SMBG or mean glucose and no difference in self-reported hypoglycemia after PCGM.…”

Section: Professional Retrospective Cgmmentioning

confidence: 99%

See 3 more Smart Citations

Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters

Wright

Hirsch

2017

Diabetes Technology & Therapeutics

138

111

View full text Add to dashboard Cite

show abstract

Section: Professional Retrospective Cgmsupporting

confidence: 48%

Section: Professional Retrospective Cgmmentioning

confidence: 89%

Section: Professional Retrospective Cgmmentioning

confidence: 89%

Section: Professional Retrospective Cgmmentioning

confidence: 99%

See 2 more Smart Citations

Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters

Wright

Hirsch

2017

Diabetes Technology & Therapeutics

138

111

View full text Add to dashboard Cite

show abstract

“…The use of continuous glucose monitoring (CGM) provides the opportunity to observe glycemic patterns over specified time periods, 5 , 6 and blinded CGM can be used to help determine glycemic variability, providing valuable information on the effectiveness and safety of experimental interventions. 7 To date, however, few studies have investigated the use of CGM in patients with type 2 diabetes receiving intensive MDI or CSII therapy. 8 , 9 For this reason, a secondary objective of the OpT2mise study was to compare the effects of CSII and MDI on glucose profiles obtained using CGM data in patients with suboptimally controlled type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study

Conget¹,

Castañeda

Petrovski

et al. 2016

Diabetes Technology & Therapeutics

Self Cite

View full text Add to dashboard Cite

Background: The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes.Research Design and Methods: Patients with glycated hemoglobin (HbA1c) levels of ≥8% (64 mmol/mol) and ≤12% (108 mmol/mol) despite insulin doses of 0.7–1.8 U/kg/day via MDI were randomized to CSII (n=168) or continued MDI (n=163). Changes in glucose profiles were evaluated using continuous glucose monitoring data collected over 6-day periods before and 6 months after randomization.Results: After 6 months, reductions in HbA1c levels were significantly greater with CSII (−1.1±1.2% [−12.0±13.1 mmol/mol]) than with MDI (−0.4±1.1% [−4.4±12.0 mmol/mol]) (P<0.001). Similarly, compared with patients receiving MDI, those receiving CSII showed significantly greater reductions in 24-h mean sensor glucose (SG) (treatment difference, −17.1 mg/dL; P=0.0023), less exposure to SG >180 mg/dL (−12.4%; P=0.0004) and SG >250 mg/dL (−5.5%; P=0.0153), and more time in the SG range of 70–180 mg/dL (12.3%; P=0.0002), with no differences in exposure to SG<70 mg/dL or in glucose variability. Changes in postprandial (4-h) glucose area under the curve >180 mg/dL were significantly greater with CSII than with MDI after breakfast (−775.9±1,441.2 mg/dL/min vs. −160.7±1,074.1 mg/dL/min; P=0.0015) and after dinner (−731.4±1,580.7 mg/dL/min vs. −71.1±1,083.5 mg/dL/min; P=0.0014).Conclusions: In patients with suboptimally controlled type 2 diabetes, CSII significantly improves selected glucometrics, compared with MDI, without increasing the risk of hypoglycemia.

show abstract

Continuous glucose monitoring shared medical appointments improve diabetes self‐efficacy and hemoglobin A1C

Simonyan

Isaacs

Lekic

et al. 2021

J Am Coll Clin Pharm

View full text Add to dashboard Cite

IntroductionDiabetes self‐management education and support and professional continuous glucose monitoring (CGM) were combined into shared medical appointments (SMA) to provide care for people with diabetes. Although the individual components have evidence of efficacy, this combination has never been studied.ObjectivesThe purpose of this study is to assess the impact of CGM SMA on diabetes self‐efficacy and hemoglobin A1C (A1C) in persons with diabetes.MethodsAdults who attended a two‐part CGM SMA at a large academic medical center were included in this retrospective, pre‐post study. The CGM SMA incorporated diabetes education, peer support, and seven days of professional CGM. The primary outcome was change in diabetes self‐efficacy through a validated eight‐item Likert Scale instrument. Secondary objectives were changes in A1C, changes in diabetes medications, and type of planned lifestyle changes. Paired t tests were used to analyze change in A1C and diabetes self‐efficacy scores.ResultsA total of 171 participants were included in this analysis. Diabetes self‐efficacy scores increased by a mean of 1.63 ± 2.09 points (P < .001) out of 10 points maximum after participation in the two‐part CGM SMA. The A1C decreased by a mean of 0.80 ± 1.52% (P < .001), with a mean follow‐up A1C of 7.8 ± 1.60%. Those with an A1C > 8% (n = 101) experienced a decrease of 1.20%. Participants utilizing the unblinded device (n = 133) experienced a decrease in A1C by 0.75% compared with 1.0% in those that utilized a blinded device (n = 38). Most medication changes made in the CGM SMA were dosage adjustments and changes in administration time.ConclusionsThe CGM SMA is a novel practice model incorporating diabetes education, peer support, professional CGM, and interprofessional care that demonstrated improvements in diabetes self‐efficacy and A1C.

show abstract

Transitory Beneficial Effects of Professional Continuous Glucose Monitoring on the Metabolic Control of Patients with Type 1 Diabetes

Abstract: Although a transient phenomenon, PCGM can be useful in the short term in improving metabolic and clinical profile of suboptimally controlled T1DM subjects, including those with repeated hypoglycemia.

Cited by 3 publications

References 13 publications

Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters

Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters

The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study

Continuous glucose monitoring shared medical appointments improve diabetes self‐efficacy and hemoglobin A1C

Contact Info

Product

Resources

About